Abstracts tagged "NAD+ booster"

Abstract Number: 0036 • ACR Convergence 2021
The NAD+ Metabolism Is Altered in Rheumatoid Arthritis and Its Modulation with NAD+ Boosters Exhibits Key Anti-Inflammatory and Anti-Oxidant Effects
Carlos Pérez-Sánchez¹, Luz Marina Sanchez-Mendoza², Nuria Barbarroja³, M.Carmen Abalos-Aguilera⁴, Maria Luque-Tevar⁵, Alejandra Patiño-Trives⁵, Iván Arias de la Rosa³, Cristobal Román-Rodriguez⁶, Juan Antonio Moreno², Maria Isabel Buron², Jose Antonio Gonzalez-Reyes², Marta Rojas-Gimenez⁴, Eduardo Collantes-Estevez⁶, alejandro Escudero⁶, Jose Manuel Villalba² and Chary lopez-pedrera⁶, ¹IMIBIC, Córdoba, Spain, ²Department of Cell Biology, Physiology and Immunology, University of Córdoba, Campus de Excelencia Internacional Agroalimentario, ceiA3, Cordoba, Spain, ³University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ⁴Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Córdoba, Cordoba, Spain, ⁵Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, ⁶IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain
Background/Purpose: NAD+ is a key cofactor and second messenger for multiple cellular processes that exhibits antioxidant, anti-apoptotic, and anti-inflammatory properties. Numerous publications and clinical trials…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].